Price movement over the last 24 hours
Alcon AG vs Abrdn Physical Platinum Shares ETF — how do they compare? Alcon AG trades at $66.64 (market cap $32.69B), while Abrdn Physical Platinum Shares ETF trades at $14.39. The key difference: Alcon AG pays a 0.54% dividend while Abrdn Physical Platinum Shares ETF pays none. Which is the better fit depends on your goals.
| ALC | PPLT | |
|---|---|---|
Market Cap | $32.69B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $92.22 | $25.23 |
52-Week Low | $62.02 | $11.78 |
Enterprise Value | $36.28B | — |
Dividend Yield | 0.54% | — |
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
PPLT, the Aberdeen Physical Platinum Shares ETF, trades at $14.83, up 0.75% on the day, amid a bearish technical outlook with moving averages signaling sell pressure. The fund recently executed a 1-for-10 stock split effective May 18, 2026, adjusting share count without altering the underlying asset value. Key financial ratios are unavailable, as the ETF holds physical platinum, not generating traditional corporate earnings or sales.
The outlook for PPLT hinges on platinum price trends, which face headwinds from weaker industrial demand and competition from gold. Recent news highlights platinum's underperformance versus other precious metals, suggesting cautious sentiment. Risks include commodity volatility and economic cycles, while potential upside relies on a sustained rally in platinum markets.
Trailing returns across standard periods
Latest headlines on both assets
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →PPLT is a physically-backed ETF designed to track the spot price of platinum, less the Trust's expenses. It holds physical platinum bullion in secure vaults, providing investors with a liquid and cost-effective way to access the platinum market without the logistical challenges of direct ownership.
Read more on PPLT →